Lisata Therapeutics vs Lyell Immunopharma
Lisata Therapeutics is the larger business, with $170,000 of revenue in fiscal 2025 against $36,000 for Lyell Immunopharma (4.7 times as much). Lyell Immunopharma grew faster (-41.0% against -83.0%). Lisata Therapeutics kept more of each dollar of sales as profit: a net margin of -9756.5% against -762355.6%. Lisata Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Lisata TherapeuticsLSTA, 2025 | Lyell ImmunopharmaLYEL, 2025 |
|---|---|---|
| Revenue | $170,000 | $36,000 |
| Revenue growth | -83.0% | -41.0% |
| Net income | −$16.6m | −$274m |
| Operating margin | -10711.2% | -748344.4% |
| Net margin | -9756.5% | -762355.6% |
| Return on equity | -74.7% | -87.0% |
| Free cash flow | −$16.0m | −$151m |
| Cash | $16.0m | $60.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 21 | 161 |
| Market value | $9.8m | $252m |
| Price vs our value range | — | — |
| Moat score | 5 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 29 sales |